arrow
E

Evan Rosenbaum

Memorial Sloan Kettering Cancer Center
H指数:17
被引数:1,152

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

在去分化脂肪肉瘤中序贯使用CDK4/6和PD-1抑制剂后的肿瘤与免疫动态变化:一项2期研究的结果

2026-02-010
PRE
A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma

一项关于CSF1R抑制剂vimseltinib与PD-L1抑制剂avelumab联合治疗晚期肉瘤的I期研究

2025-07-250
OAAI
Immunologic correlates in a CIC::DUX4 fusion-positive sarcoma responsive to dual immune checkpoint blockade

免疫学相关指标在一例对双重免疫检查点阻断敏感的CIC::DUX4融合阳性肉瘤中的表现

2025-03-250
OA
Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas

外周血(PB)T细胞表型和肿瘤微环境(TME)亚型与肉瘤中免疫检查点阻断(ICB)的疗效独立相关

2024-09-010
PRE
Low-grade fi bromyxoid sarcoma and sclerosing epithelioid fi brosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group
2024-09-010
OAAI
Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naive, advanced gastrointestinal stromal tumor (GIST)

循环肿瘤DNA(ctDNA)作为分子生物标志物在伊马替尼联合比尼替尼治疗初治、晚期胃肠道间质瘤(GIST)II期试验中的价值

2024-09-010
PRE
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery

针对GM2,GD2和GD3的三价神经节苷脂疫苗联合免疫佐剂OPT-821与单独OPT-821在转移性肉瘤患者中的随机II期试验

2022-11-019
OAAI
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
2022-06-1631
OAAI
Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

软组织和骨肉瘤的临床测序描绘了不同的基因组景观和潜在的治疗靶点

2022-06-15100
OAAI